Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial

References

• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–2581. doi:10.1001/jama.287.19.2570
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019. doi:10.1093/eurheartj/ehz486
   Web of Science ®Google Scholar
• Ninomiya T. Japanese legacy cohort studies: the Hisayama study. J Epidemiol. 2018;28(11):444–451. doi:10.2188/jea.JE20180150
   PubMedGoogle Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393. doi:10.1056/NEJMoa021778
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. doi:10.1016/j.cmet.2006.01.004
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. doi:10.1001/jama.2018.18269
   PubMed Web of Science ®Google Scholar
• Ross R, Epstein FH. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126. doi:10.1056/NEJM199901143400207
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646
   PubMed Web of Science ®Google Scholar
• Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499–3507. doi:10.1093/eurheartj/ehy310
   PubMed Web of Science ®Google Scholar
• Tomovic K, Lazarevic J, Kocic G, et al. Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection. Med Res Rev. 2019;39(1):404–422. doi:10.1002/med.21513
   PubMedGoogle Scholar
• Morimoto T, Sakuma I, Sakuma M, et al. Randomized evaluation of anagliptin vs sitagliptin on low-density lipoproteiN cholesterol in diabetes (REASON) trial: a 52-week, open-label, randomized clinical trial. Sci Rep. 2019;9(1):8537. doi:10.1038/s41598-019-44885-x
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182. doi:10.1016/S0140-6736(09)60447-5
   PubMed Web of Science ®Google Scholar
• Ueda S, Shimabukuro M, Arasaki O, et al. Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk: rationale and study design of the REASON trial. Cardiovasc Drugs Ther. 2018;32(1):73–80. doi:10.1007/s10557-018-6776-z
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein A. The new cholesterol treatment guidelines. N Engl J Med. 2014;370(20):1957. doi:10.1056/NEJMc1403438
   PubMedGoogle Scholar
• Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol. 2007;49(3):290–297. doi:10.1016/j.jacc.2006.08.054
   PubMedGoogle Scholar
• Zhao Y, He X, Huang C, et al. The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysis. Diabetes Res Clin Pract. 2010;90(3):279–287. doi:10.1016/j.diabres.2010.09.011
   PubMedGoogle Scholar
• Mazidi M, Karimi E, Rezaie P, et al. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications. 2017;31(7):1237–1242. doi:10.1016/j.jdiacomp.2016.05.022
   PubMed Web of Science ®Google Scholar
• Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. doi:10.1155/2016/3094642
   PubMed Web of Science ®Google Scholar
• Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–37. doi:10.1016/j.metabol.2018.02.002
   PubMed Web of Science ®Google Scholar
• Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62(3):347–351. doi:10.1016/j.metabol.2012.09.004
   PubMed Web of Science ®Google Scholar
• Nakamura K, Oe H, Kihara H, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110. doi:10.1186/s12933-014-0110-2
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Deacon CF, et al. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism. 2014;63(9):1141–1148. doi:10.1016/j.metabol.2014.06.004
   PubMed Web of Science ®Google Scholar
• Kakuda H, Kobayashi J, Kakuda M, et al. The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes. Endocrine. 2015;48(3):1005–1009. doi:10.1007/s12020-014-0376-x
   PubMed Web of Science ®Google Scholar
• Nomoto H, Miyoshi H, Furumoto T, et al. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: sapporo athero-incretin study 1 (SAIS1). PLoS One. 2016;11(10):e0164255. doi:10.1371/journal.pone.0164255
   PubMedGoogle Scholar
• Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha(1-67) in patients with type 2 diabetes. Diabetes Care. 2017;40(8):1073–1081. doi:10.2337/dc17-0061
   PubMed Web of Science ®Google Scholar
• Zhong J, Rao X, Deiuliis J, et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes. 2013;62(1):149–157. doi:10.2337/db12-0230
   PubMedGoogle Scholar
• Shi S, Koya D, Kanasaki K. Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair. 2016;9:1. doi:10.1186/s13069-016-0038-0
   PubMedGoogle Scholar
• Romacho T, Vallejo S, Villalobos LA, et al. Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release. J Hypertens. 2016;34(5):869–876. doi:10.1097/HJH.0000000000000886
   PubMedGoogle Scholar
• Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511. doi:10.1161/01.cir.0000052939.59093.45
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64–70. doi:10.1001/jama.286.1.64
   PubMed Web of Science ®Google Scholar
• Mustonen K, Keski-Nisula L, Vaarala O, et al. Few associations between high-sensitivity C-reactive protein and environmental factors in 4.5-year-old children. Pediatr Allergy Immunol. 2012;23(6):522–528. doi:10.1111/j.1399-3038.2012.01306.x
   PubMedGoogle Scholar